India, June 8 -- Today's top gainers include Tango Therapeutics, following encouraging pancreatic cancer trial data; Aspire Biopharma, ahead of upcoming milestones; Alvotech, after FDA acceptance of its interchangeable biosimilar to Entyvio for review; and Zevra Therapeutics, on actions strengthening exclusivity for MIPLYFFA, among others.
Read on.
Tango Puts Its Best Foot Forward
Tango Therapeutics Inc. (TNGX) led the pack of gainers on Monday, with shares jumping more than 50%, following positive initial data from its ongoing Phase 1/2 combination study of Vopimetostat in pancreatic cancer.
The phase 1/2 trial is a combination study of Vopimetostat with RAS(ON) multi-selective inhibitor Daraxonrasib or RAS(ON) G12D-selective inhibitor...